Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Eli Lilly & Co.
LLYHealthcareGenerated Jul 5, 2026, 08:10 PM UTC
LLY (Eli Lilly & Co.) analytical snapshot. Revenue grew +19.6% YoY to $34.12B. 5-year revenue CAGR +8.9%; 10y CAGR +6.3%. Net margin at 15.36% (contracting ▼). Market cap $1.14T at $1213.91 per share. Trailing P/E 209.29, P/S 33.50, P/B 36.64. Graham number $65.75 (trades above intrinsic). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 3 (data confidence 74%). Descriptive analytics from public filings — not investment advice.
Market cap
$1.14T
941.74M shares
Price
$1213.91
NYQ
P/E (ttm)
209.29
Revenue (FY)
$34.12B
YoY +19.6%
Net margin
15.36%
▼ 9.88pp
Free cash flow
—
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 35Improving
60% conf
Revenue grew +19.6% YoY to $34.12B. 5-year revenue CAGR +8.9%; 10y CAGR +6.3%. Net margin at 15.36% (contracting ▼).
- Revenue grew +19.6% YoY to $34.12B.
- 5-year revenue CAGR +8.9%; 10y CAGR +6.3%.
- Net margin at 15.36% (contracting ▼).
- Return on equity 36.72%, ROA 6.66%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Net income down ▼ +16.1% YoY.
- Debt/equity 0.94, current ratio 1.50, net debt $24.19B.
- Asset turnover 0.29 — capital efficiency.
Revenue (FY)
$34.12B
YoY +19.6%
Net margin
15.36%
▼ 9.88pp
ROE
36.72%
ROA 6.66%
ROIC
0.00%
EPS (diluted)
$5.80
FY2025
Free cash flow
—
Debt / equity
0.94
Cash $5.28B
Current ratio
1.50
Equity $31.20B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $19.62B | — | 0.00 | 0.00 | 12.19 | — | 13.56 |
| 2017 | $19.96B | +1.7% | 0.00 | 0.00 | 12.07 | — | 15.67 |
| 2018 | $18.31B | -8.2% | 0.00 | 0.00 | 14.95 | — | 23.62 |
| 2019 | $19.97B | +9.1% | 0.00 | 0.00 | -1.02 | — | -2.08 |
| 2020 | $21.49B | +7.6% | 0.00 | 0.00 | 15.04 | — | 123.98 |
| 2021 | $22.32B | +3.8% | 0.00 | 0.00 | 37.27 | — | 147.45 |
| 2022 | $24.54B | +9.9% | 0.00 | 0.00 | 25.24 | — | 68.98 |
| 2023 | $28.32B | +15.4% | 0.00 | 0.00 | 19.71 | — | 52.41 |
| 2024 | $28.54B | +0.8% | 0.00 | 0.00 | 21.88 | — | 57.97 |
| 2025 | $34.12B | +19.6% | 0.00 | 0.00 | 15.36 | — | 36.72 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $12.73B | +45.2% | — | 21.68% |
| Jun 30, 2025 | $28.29B | +40.9% | +122.2% | 29.77% |
| Jun 30, 2025 | $15.56B | -22.5% | -45.0% | 54.12% |
| Sep 30, 2025 | $45.89B | +45.6% | +194.9% | 30.51% |
| Sep 30, 2025 | $17.60B | -44.1% | -61.6% | 79.55% |
| Mar 31, 2026 | $19.80B | +55.5% | +12.5% | 37.36% |
Revenue (annual, SEC 10-K)
2016: 19,616
2017: 19,959
2018: 18,313
2019: 19,974
2020: 21,493
2021: 22,320
2022: 24,540
2023: 28,318
2024: 28,541
2025: 34,124
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Apr 30, 2026. 5 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed Apr 30, 2026.
- 5 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Eli Lilly & Co.; broad institutional reporting.
- Recent filers include PROVIDENT ADVISORS LLC, INTRUST BANK NA, PROVIDENT INVESTMENT ADVISORS INC.
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 12, 2026
Annual report
Latest 10-Q
Apr 30, 2026
8-K (recent)
5
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| PROVIDENT ADVISORS LLC | 13F-HR | Aug 13, 2004 |
| INTRUST BANK NA | 13F-HR | Feb 7, 2001 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Apr 27, 2001 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Apr 15, 2003 |
| PROVIDENT INVESTMENT ADVISORS INC | 13F-HR | Jul 16, 2003 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 20, 2026 | 8-K | 8-K |
| May 7, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Feb 4, 2026 | 8-K | 8-K |
| Nov 21, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -49Deteriorating
64% conf
3 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 20 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Restatement of financial statements: The term "restate" "financial statements" appears in 5 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- R&D intensity declining: R&D as % of revenue fell from 19.6% to 17.5%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Going concern doubt.
- Ongoing high-severity risk language: Material weakness in internal controls, Restatement of financial statements.
Revenue
$34.12B
+19.6% YoY
Net income
$5.24B
-16.1% YoY
Operating cash flow
$4.24B
-44.1% YoY
Total assets
$78.72B
+23.0% YoY
Long-term debt
$19.10B
+29.0% YoY
Cash & equivalents
$3.27B
+15.9% YoY
Stockholders equity
$14.27B
+32.5% YoY
Inventory
$7.59B
+31.5% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $28.54B | $34.12B | $5.58B | +19.6% |
| Net income | $6.24B | $5.24B | $-1.00B | -16.1% |
| Operating cash flow | $7.59B | $4.24B | $-3.35B | -44.1% |
| Total assets | $64.01B | $78.72B | $14.71B | +23.0% |
| Long-term debt | $14.82B | $19.10B | $4.29B | +29.0% |
| Cash & equivalents | $2.82B | $3.27B | $449.4M | +15.9% |
| Stockholders equity | $10.77B | $14.27B | $3.50B | +32.5% |
| Inventory | $5.77B | $7.59B | $1.82B | +31.5% |
| Accounts receivable | $9.09B | $11.01B | $1.92B | +21.1% |
| R&D expense | $5.59B | $5.98B | $381.3M | +6.8% |
| SG&A expense | $6.44B | $7.40B | $963.6M | +15.0% |
| Interest expense | $359.6M | $339.8M | $-19.8M | -5.5% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AllowanceForDoubtfulAccountsReceivableCurrent, AmortizationOfIntangibleAssets, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax, AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 1 | 0 | NEW |
| Material weakness in internal controls | high | 20 | 2 | Ongoing |
| Restatement of financial statements | high | 5 | 1 | Ongoing |
| Impairment charge | medium | 38 | 4 | Ongoing |
| Restructuring | medium | 118 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 25 | 2 | Ongoing |
| Related party transactions | low | 1 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 0
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $1.14T at $1213.91 per share.
- ProPrice & TechnicalsPrice $1213.91 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 3
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Eli Lilly & Co. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewRevenue grew **+19.6%** YoY to $34.12B..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow LLY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY● you | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Danaher Corp. DHR | — | Neutral |
| Intuitive Surgical Inc. ISRG | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |
| Illumina Inc. ILMN | — | Neutral |